Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Fecal microbiota transplant shows promise for hepatic encephalopathy

Key clinical point: Fecal microbiota transplant was safe and showed suggestions of effectiveness in a pilot, phase 1 study of patients with recurrent hepatic encephalopathy.

Major finding: Average Offtime+Ontime in the EncephalApp test fell by a clinically meaningful 51 seconds from baseline to follow-up.

Study details: A single-center, phase 1 safety study with 20 randomized patients.

Disclosures: Dr. Bajaj had no relevant disclosures.

Citation:

Bajaj JS et al. J Hepatol. 2019 April;70(1):e55.